Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Supporting Mental Health on Suicide Prevention Day: Mednet’s Commitment to Changing the Narrative

As part of Suicide Prevention Day, we take a look at the different ways we can support our colleagues' mental health and wellbeing and change the narrative around suicide

Mednet

- PMLiVE

Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m

The companies will use Genetic Leap's AI platform to generate oligonucleotide drugs against targets selected by Lilly

- PMLiVE

GSK shares positive phase 3 results for long-acting biologic in severe asthma

Depemokimab is designed to allow for six-month dosing intervals for patients with the lung condition

regeneron headquarters

Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

Avalere Health appoints Corrina Safeio as president, global marketing

Safeio will also serve as executive vice president, corporate communications, and on the leadership team

- PMLiVE

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Join the live webinar on Thursday 3rd October at 1.00pm (BST), featuring panellists from Mtech Access, Arcturis, and Delta Hat.

Petauri Evidence

- PMLiVE

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

- PMLiVE

J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC

The chemotherapy-free regimen was approved in the US last month for advanced lung cancer patients

- PMLiVE

Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

It is hoped that a once-weekly treatment option could improve adherence rates

- PMLiVE

What are “orphan drugs” and how do we navigate the challenges of writing about them?

The first in our 'Ask Alex' series, where Principal Medical Writer, Dr Alexandra Loveday answers some frequently asked questions about Medcomms. This week, she takes a look at 'orphan drugs',...

Mednet

- PMLiVE

GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

The chronic respiratory disease affects more than 300 million people globally

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links